| abstract |
A method is described to increase the maximum tolerated dose and thus the efficacy of an acetylcholine esterase inhibitor (AChEI) in a patient suffering from Alzheimer's dementia by decreasing concomitant adverse effects by administering AChEI in combination. with an anticholinergic, peripheral, non-selective agent, whereby an improved inhibition of acetylcholine esterase in the CNS of the patient is achieved and the relief of dementia symptoms of the Alzheimer type in the patient is thereby improved to a greater degree. Also described is the use of an anticholinergic, peripheral, non-selective agent (nsPAChA) for the preparation of a pharmaceutical composition to increase the maximum tolerated dose and thus the efficacy of an acetylcholine esterase inhibitor (AChEI) in a patient suffering from of dementia of the Alzheimer type and pharmaceutical compositions comprising a peripheral, non-selective anticholinergic agent of formula II as illustrated in the description and an acetylcholine esterase inhibitor. |